REPRONEX 75 UNIT — DIN 02247790
MENOTROPINS : 75 UNIT · FERRING INC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is REPRONEX?
REPRONEX 75 UNIT contains MENOTROPINS : 75 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02247790, held by FERRING INC, supplied as POWDER FOR SOLUTION for INTRAMUSCULAR ; SUBCUTANEOUS administration. Health Canada currently lists it as cancelled post market, status dated 23-Apr-2019. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is REPRONEX used for?
Multiple follicular development (controlled ovarian stimulation) and induction of ovulation in infertile patients who have previously received pituitary suppression.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Human Menopausal Gonadotrophin cost around the world?
Human Menopausal Gonadotrophin is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Czechia | max producer price (ex-factory) | 2 | 9 | CZK███.██ |
| Greece | producer price (ex-factory) | 8 | 8 | EUR███.██ |
| Saudi Arabia | public | 5 | 6 | SAR███.██ |
| Luxembourg | reimbursement | 5 | 5 | EUR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 1 | 2 | EUR███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
31 pack listings across 22 brand entries and 5 price bases, refreshed 05 Sep 2026. Ranges span every Human Menopausal Gonadotrophin pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Human Menopausal Gonadotrophin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Human Menopausal Gonadotrophin, across 4 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| FERRING INC | 2 | 1 | MENOPUR, REPRONEX | Sourceable in Canada |
| EMD SERONO, A DIVISION OF EMD INC., CANADA | 1 | 0 | PERGONAL 75 I.U. | No marketed DIN |
| ORGANON CANADA LTD LTEE | 1 | 0 | HUMEGON INJ 75 I.U. | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 75 UNIT |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAMUSCULAR ; SUBCUTANEOUS |
| Pack configuration (monograph) | Boxes of 5 vials of Repronex + 5 vials of diluent (0.9% Sodium Chloride Injection, USP). |
| Storage | Lyophilized powder: Store at 15°C - 25°C. Protect from light. Reconstituted solution: Use immediately. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Human Menopausal Gonadotrophin |
|---|---|
| ATC code | G03GA02 |
| AHFS class | 68:18.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02247790 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2247790 |
| Brand name | REPRONEX |
| Generic / active ingredient | MENOTROPINS : 75 UNIT |
| Market authorization holder | FERRING INC |
| Health Canada schedule | Prescription |
| ATC code | G03GA02 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G03GA |
| Current status | CANCELLED POST MARKET |
| Status date | 23-Apr-2019 |
| Original market date | 2003-08-28 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Individualized. Typically 150-225 IU daily for 5 days, adjusted based on response. Max 450 IU/day. Dosing >12 days not recommended. Follow with hCG to induce ovulation. SC or IM administration.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Primary ovarian failure (high FSH), uncontrolled thyroid/adrenal dysfunction, intracranial lesions (pituitary tumor), non-anovulatory infertility (unless IVF), abnormal bleeding, ovarian cysts.
Warnings and precautions
Risk of Ovarian Hyperstimulation Syndrome (OHSS), pulmonary and vascular complications (thrombosis, embolism), multiple births, and hypersensitivity/anaphylactic reactions.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 4 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| MENOPUR | 75 UNIT | POWDER FOR SOLUTION | FERRING INC | MARKETED | 02283093 |
| HUMEGON INJ 75 I.U. | .9 % | LIQUID ; POWDER FOR SOLUTION | ORGANON CANADA LTD LTEE | CANCELLED POST MARKET | 01958992 |
| PERGONAL 75 I.U. | 75 UNIT | POWDER FOR SOLUTION | EMD SERONO, A DIVISION OF EMD INC., CANADA | CANCELLED POST MARKET | 00254916 |
2 · Same class — other molecules in ATC G03GA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Follitropin Alfa | GONAL-F · GONAL-F PEN | 10 | 3 | Yes |
| Follitropin Delta | REKOVELLE | 6 | 3 | Yes |
| Combinations | PERGOVERIS | 4 | 3 | Yes |
| Chorionic Gonadotrophin | A.P.L. - PWS-LIQ · APL INJ 1000 IU/ML · CHORIONIC GONADOTROPIN FOR INJECTION, USP · PREGNYL · +2 more | 6 | 2 | Yes |
| Choriogonadotropin Alfa | OVIDREL | 2 | 2 | Yes |
| Follitropin Beta | PUREGON · PUREGON (600 IU) · PUREGON 100 I.U. · PUREGON 50 I.U. | 6 | 1 | Yes |
| Human Menopausal Gonadotrophin | HUMEGON INJ 75 I.U. · MENOPUR · PERGONAL 75 I.U. · REPRONEX | 4 | 1 | Yes |
| Urofollitropin | BRAVELLE · FERTINORM HP 150 - PWS DILUENT IM SC · FERTINORM HP 75 - PWS DILUENT IM SC · METRODIN 75 I.U. | 4 | 0 | Not in Canada |
| Lutropin Alfa | LUVERIS | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC G03G
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| G03GB | Clomifene | 4 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is REPRONEX called?
The same molecule, Human Menopausal Gonadotrophin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| MERIOFERT SET | Latin | Czechia |
| MENOPUR | Latin | Czechia |
| MENOPUR Multidose | Latin | Saudi Arabia |
| Merional HG | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.